Van Dam_2008_Psychopharmacology.(Berl)_197_37

Reference

Title : Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease - Van Dam_2008_Psychopharmacology.(Berl)_197_37
Author(s) : Van Dam D , Coen K , De Deyn PP
Ref : Psychopharmacology (Berl) , 197 :37 , 2008
Abstract :

RATIONALE: The interest for acetylcholinesterase inhibitors in the treatment of Alzheimer's disease has been greatly renewed owing to the discovery of a broad range of additional cholinergic and non-cholinergic effects, exploitable to maximize the efficacy of these drugs beyond merely improving intellectual functions at the symptomatic level. OBJECTIVES: The age-dependent cognitive decline in the valid APP23 transgenic mouse model for Alzheimer's disease was employed to evaluate disease-modifying efficacy of chronic treatment with donepezil. MATERIALS AND
METHODS: At age 6 weeks, heterozygous APP23 mice and control littermates were subcutaneously implanted with osmotic pumps delivering saline or donepezil (0.27 or 0.58 mg/kg per day). After 2 months of treatment, a 3-week wash-out period was allowed to prevent bias from sustained symptomatic effects before cognitive evaluation in the Morris water maze commenced.
RESULTS: Donepezil (0.27 mg/kg per day)-treated APP23 mice performed significantly better than their sham-treated counterparts during the Morris water maze acquisition phase and the subsequent probe or retention trial. Chronic donepezil (0.27 mg/kg per day) treatment improved spatial accuracy in APP23 mice as to reach the same level of performance as wild-type control animals on this complex visual-spatial learning task. CONCLUSION: This is the first study reporting disease-modifying efficacy of donepezil at the level of cognitive performance in transgenic mice modeling Alzheimer's disease.

PubMedSearch : Van Dam_2008_Psychopharmacology.(Berl)_197_37
PubMedID: 18008065

Related information

Citations formats

Van Dam D, Coen K, De Deyn PP (2008)
Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease
Psychopharmacology (Berl) 197 :37

Van Dam D, Coen K, De Deyn PP (2008)
Psychopharmacology (Berl) 197 :37